• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

PLoS One . Validation of two severity scores as predictors for outcome in Coronavirus Disease 2019 (COVID-19)

tetano

Editor, Senior Moderator
PLoS One


. 2021 Feb 19;16(2):e0247488.
doi: 10.1371/journal.pone.0247488. eCollection 2021.
Validation of two severity scores as predictors for outcome in Coronavirus Disease 2019 (COVID-19)


Christian Salbach[SUP] 1 [/SUP], Matthias Mueller-Hennessen[SUP] 1 [/SUP], Moritz Biener[SUP] 1 [/SUP], Kiril M Stoyanov[SUP] 1 [/SUP], Mehrshad Vafaie[SUP] 1 [/SUP], Michael R Preusch[SUP] 1 [/SUP], Lars P Kihm[SUP] 2 [/SUP], Uta Merle[SUP] 3 [/SUP], Paul Schnitzler[SUP] 4 [/SUP], Hugo A Katus[SUP] 1 [/SUP], Evangelos Giannitsis[SUP] 1 [/SUP]



Affiliations

Abstract

Background: An established objective and standardized reporting of clinical severity and disease progression in COVID-19 is still not established. We validated and compared the usefulness of two classification systems reported earlier-a severity grading proposed by Siddiqi and a system from the National Australian COVID-19 guideline. Both had not been validated externally and were now tested for their ability to predict complications.
Methods: In this retrospective, single-centre observational study, patients hospitalized with confirmed COVID-19 across all severity stages were enrolled. The clinical severity was graded at admission and during hospitalization. Multivariate Cox regression was used to identify independent risk factors for mortality, a composite primary (mortality, incident acute respiratory distress syndrome, incident mechanical ventilation), a secondary endpoint (mortality, incident acute myocardial injury, incident venous thrombosis, pulmonary embolism or stroke) and progression of severity grades.
Results: Of 109 patients 17 died, 31 and 48 developed the primary and secondary endpoint, respectively. Worsening of the severity grade by at least one stage occurred in 27 and 28 patients, respectively. Siddiqi and Australian classification were identified as independent predictors for the primary endpoint (adjusted hazard ratio (aHR) 2.30, p<0.001 and aHR 2.08, p<0.001), for the secondary endpoint (aHR 2.12, p<0.001 and aHR 1.79, p<0.001) and mortality (aHR 2.30, p = 0.071 and aHR 1.98, p = 0.017). Both classification systems showed very good agreement regarding initial grading and good agreement regarding progression of severity stages.
Conclusions: Standardized and objective severity grading is useful to unequivocally stratify patients presenting with COVID-19 for their individual risk of complications.
 
Back
Top Bottom